Biodesix, Inc. (BDSX)

NASDAQ: BDSX · Real-Time Price · USD
0.3020
-0.0235 (-7.22%)
At close: May 30, 2025, 4:00 PM
0.3102
+0.0082 (2.72%)
After-hours: May 30, 2025, 7:59 PM EDT
-7.22%
Market Cap 44.09M
Revenue (ttm) 74.46M
Net Income (ttm) -40.42M
Shares Out 145.98M
EPS (ttm) -0.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,133,091
Open 0.3202
Previous Close 0.3255
Day's Range 0.2906 - 0.3262
52-Week Range 0.1718 - 2.0400
Beta 1.17
Analysts Strong Buy
Price Target 1.75 (+479.47%)
Earnings Date May 13, 2025

About BDSX

Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to... [Read more]

Sector Healthcare
IPO Date Oct 28, 2020
Employees 273
Stock Exchange NASDAQ
Ticker Symbol BDSX
Full Company Profile

Financial Performance

In 2024, Biodesix's revenue was $71.32 million, an increase of 45.30% compared to the previous year's $49.09 million. Losses were -$42.93 million, -17.67% less than in 2023.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for BDSX stock is "Strong Buy." The 12-month stock price forecast is $1.75, which is an increase of 479.47% from the latest price.

Price Target
$1.75
(479.47% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting

LOUISVILLE, Colo., May 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that new data will be presented at the 2025 American Society ...

8 days ago - GlobeNewsWire

Biodesix to Participate in Upcoming Investor Conferences

LOUISVILLE, Colo., May 21, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that members of the Biodesix management team, will participat...

9 days ago - GlobeNewsWire

Biodesix Announces New Clinical and Economic Data for its Nodify Lung® Tests at ISPOR and ATS

LOUISVILLE, Colo., May 15, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced that new data will be presented at the International Society for Ph...

15 days ago - GlobeNewsWire

Denver Post Names Biodesix a Winner of Top Workplaces 2025 Award

LOUISVILLE, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, is pleased to announce that it is a Colorado Top Workplaces 2025 Winner.

16 days ago - GlobeNewsWire

Biodesix, Inc. (BDSX) Q1 2025 Earnings Call Transcript

Biodesix, Inc. (NASDAQ:BDSX) Q1 2025 Results Conference Call May 13, 2025 4:30 PM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper Cowie ...

17 days ago - Seeking Alpha

Biodesix Announces First Quarter 2025 Results and Highlights

Total Q1 2025 Revenue of $18.0 million, an increase of 21% over Q1 2024; Gross margins of 79.4% for Q1 2025 ; Q1 2025 Net loss improved by 18% compared to Q1 2024; Updated 2025 Revenue Guidance to a r...

17 days ago - GlobeNewsWire

Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025

LOUISVILLE, Colo., April 29, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the first quarte...

4 weeks ago - GlobeNewsWire

Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types

Aggregate analysis of eight clinical trials of patients with advanced non-small cell lung cancer (aNSCLC) was supported by Biodesix, using Bio-Rad Droplet Digital™ PCR technology Aggregate analysis of...

5 weeks ago - GlobeNewsWire

Biodesix, Inc. (BDSX) Q4 2024 Earnings Call Transcript

Biodesix, Inc. (NASDAQ:BDSX) Q4 2024 Earnings Conference Call March 3, 2025 4:30 PM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper Cowi...

3 months ago - Seeking Alpha

Biodesix Announces Fourth Quarter and Fiscal Year 2024 Results

Total Revenue of $71.3 million for FY2024, growing 45% over FY2023; Gross margins of 78% for FY2024, up 5% points over FY2023 ; FY2025 Total Revenue Guidance of $92-95 million; Conference Call and Web...

3 months ago - GlobeNewsWire

Biodesix to Present at TD Cowen 45th Annual Health Care Conference

BOULDER, Colo., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief F...

3 months ago - GlobeNewsWire

Biodesix to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

BOULDER, Colo., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the fourth quarter a...

3 months ago - GlobeNewsWire

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited)

Grew full-year revenue to an estimated $71.3 million, an increase of 45% Grew full-year revenue to an estimated $71.3 million, an increase of 45%

5 months ago - GlobeNewsWire

Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study

Analysis of 447 patients receiving the Nodify CDT blood-based lung nodule test published in CHEST Pulmonary Journal reaffirms test performance Analysis of 447 patients receiving the Nodify CDT blood-b...

5 months ago - GlobeNewsWire

Biodesix, Inc. (BDSX) Q3 2024 Earnings Call Transcript

Biodesix, Inc. (NASDAQ:BDSX) Q3 2024 Earnings Conference Call November 1, 2024 8:30 AM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper C...

7 months ago - Seeking Alpha

Biodesix Announces Third Quarter 2024 Results and Highlights

Q3 2024 revenue grew 35% over Q3 2023 to $18.2 million; Q3 2024 gross profit margin of 77.0%, up from 76.1% in Q3 2023; Q3 2024 Net loss improved by 6% compared to Q3 2023; Conference Call and Webcast...

7 months ago - GlobeNewsWire

Biodesix to Participate in Three Investor Conferences in November

LOUISVILLE, Colo., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive O...

7 months ago - GlobeNewsWire

Biodesix to Report Third Quarter 2024 Financial Results on November 1, 2024

LOUISVILLE, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the t...

8 months ago - Business Wire

Biodesix Announces New Data Presentation at CHEST 2024 Annual Meeting and the Launch of a Complementary Clinical Study

LOUISVILLE, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data will be presented at the CHEST Ann...

8 months ago - Business Wire

Biodesix to Present at Two Investor Conferences in September

LOUISVILLE, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that members of the Biodesix management team wil...

9 months ago - Business Wire

Biodesix, Inc. (BDSX) Q2 2024 Earnings Call Transcript

Biodesix, Inc. (NASDAQ:BDSX) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Chris Brinzey - IR Scott Hutton - CEO Robin Harper Cowie - CFO Conference Call Participant...

10 months ago - Seeking Alpha

Biodesix Announces Second Quarter 2024 Results and Highlights

LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the second q...

10 months ago - Business Wire

Biodesix to Present at Canaccord Genuity's 44th Annual Growth Conference

LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chie...

10 months ago - Business Wire

Biodesix to Report Second Quarter 2024 Financial Results on August 7, 2024

LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that it will release financial results for the secon...

11 months ago - Business Wire

Biodesix Named to Inc. Magazine's 2024 “Best Workplaces”

LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, is honored to announce it has been named to Inc. Magazine's Best Wor...

1 year ago - Business Wire